Evidence map›Paper›PMID 41219823›Full record

ArticleGenome biology2025

Uli-epic: profiling RNA modifications from ultra-low input samples.

Weizhi He, Chu Xu, Wen Chen, Xiao Jiang, Yuhang Wang, Yong Peng, Shujuan Chang, Wei Zhu, Jiuhong Kang, Lulu Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weizhi He *Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Chu Xu *Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Wen Chen *Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, National Stem Cell Translational Resource Center, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Xiao JiangCancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yuhang WangClinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, National Stem Cell Translational Resource Center, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Yong PengInnovative Institute of Chinese Medicine and Pharmacy, Institute of Herbgenomics, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Shujuan ChangClinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, National Stem Cell Translational Resource Center, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Wei ZhuClinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, National Stem Cell Translational Resource Center, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Jiuhong KangClinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, National Stem Cell Translational Resource Center, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. jhkang@tongji.edu.cn.
Lulu HuCancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China. luluhu@fudan.edu.cn.

Funding

General Program of National Natural Science Foundation of China 32471340General Program of National Natural Science Foundation of China 82271723National Key Research and Development Program of China 2021YFA1100400National Natural Science Foundation of China 82230054Natural science foundation of Science and Technology Commission of Shanghai Municipality 21ZR1480300
6 · The paper itself

Abstract

High-throughput sequencing with chemical labeling enables robust, transcriptome-wide detection of RNA modifications at single-nucleotide resolution. However, these methods typically require substantial RNA amounts due to harsh treatments. We introduce Uli-epic, an innovative library construction strategy that enables profiling epitranscriptomic modifications using 100 pg to 1 ng of RNA. Utilizing Uli-epic BID-seq, we investigate pseudouridine (Ψ) sites in neural stem cells and sperm RNA from wild-type and fetal growth restriction mice, using only 500 pg of rRNA-depleted RNA. Uli-epic GLORI quantifies m

Indexed as

Gene Expression ProfilingHigh-Throughput Nucleotide SequencingRNARNA Processing, Post-TranscriptionalAnimalsFetal Growth RetardationGene LibraryMaleMiceNeural Stem CellsPseudouridineSequence Analysis, RNASpermatozoaTranscriptomePseudouridineRNABID-seqFetal growth restrictionGLORILinear amplificationM6AUli-epicUltra-low inputΨ

Identifiers

PMID41219823
PMCPMC12606830

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.